Patent affirms efficacy of vaccine developed by China – Global Times

In further vaccine developments in news, pertaining to the vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics, in China's Global Times on Sunday, it reports that local authorities have granted the first invention patent to it.

This news could underpin a positive risk theme in forex to start the week, coinciding with the improved tone over Sino/US trade relations.

Key notes

The vaccine is a recombinant adenovirus vaccine named Ad5-nCoV co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc, one of the vaccine candidate's co-developers, with the other being a team led by Chinese military infectious disease expert Chen Wei. 

The grant of the patent further confirmed the vaccine's efficacy and safety, and convincingly demonstrated the ownership of its intellectual property rights (IPR), CanSino said in a statement sent to the Global Times on Sunday. 

Xu Xinming, a Beijing-based lawyer specializing in intellectual property rights, told the Global Times on Sunday that "the grant of the patent demonstrates the vaccine's originality and creativity," noting that CanSino is also probably applying for a patent with foreign authorities to protect its IPR during international cooperation. 
 

Meanwhile, US President Donald Trump on Friday repeated his view that the trade deal was “doing very well”.

• US-China trade deal review postponed